Efesovir
Phase 2Small molecule
Efesovir is one of 18 small molecule programs targeting COVID-19. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Singulair
AstraZenecaPreclinical
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Efesovir
SScientific Center for Anti-infectious Drugs, Kazakhstan
Phase 2
Disease-Modifying Anti-Rheumatic Drugs
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-191 trial
"Efesovir" (FS-1) for COVID-19, Phase 2
Not yet recruiting·SScientific Center for Anti-infectious Drugs, Kazakhstan·Phase 2·NCT05060705·62 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Efesovir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details